TL;DR, SNO 2026, the 31st Annual Meeting and Education Day of the Society for Neuro-Oncology, runs November 12-15, 2026 at the Pennsylvania Convention Center in Philadelphia. It gathers roughly 3,000 neurosurgeons, radiation oncologists, medical oncologists, neuropathologists, and brain tumor researchers, the entire U.S. brain tumor treatment community in one building. Booth costs are mid-tier, with an estimated all-in 10x10 cost of $8,000-$18,000, unusually efficient for an audience this targeted. The floor is dominated by pharma, so device and diagnostics vendors win by leading with peer-reviewed evidence, targeting tumor boards rather than individual titles, and treating the meeting as the front door to an academic buying cycle that runs on trials, committees, and multi-year budgets. Full profile data lives on our SNO 2026 conference page.

What SNO Is, and Why Philadelphia 2026 Matters

The Society for Neuro-Oncology is the professional home of the clinicians and researchers who treat brain and central nervous system tumors: neurosurgeons, radiation oncologists, medical oncologists, neuropathologists, neuroradiologists, and the translational scientists running the trials that define standard of care. The SNO Annual Meeting is the one meeting each year where this entire community convenes. There is no broader oncology or neurosurgery show where the concentration of brain tumor decision-makers comes close.

SNO 2026 is the 31st Annual Meeting and Education Day, running November 12-15, 2026 at the Pennsylvania Convention Center in Philadelphia. The convention center venue matters for exhibitors: unlike hotel-based specialty meetings, Philadelphia supports full exhibit builds, proper demo stations, and imaging equipment on the floor. The mid-November timing places SNO at the tail of the calendar-year budget cycle and the front of next year's planning cycle for academic medical centers, which is exactly when brain tumor program directors are deciding which technologies, trials, and vendor relationships carry into the new year.

The audience is narrow by design, and that is the entire point. About 3,000 attendees, an estimated 55% with direct purchasing authority, and roughly a quarter traveling internationally. If your product is used in the diagnosis or treatment of brain and CNS tumors, this is the most efficient room you will enter all year. If it is not, SNO is a show to skip, and we say so plainly on our SNO 2026 profile.

SNO 2026: The Numbers You Need

The math worth noticing is cost per qualified buyer. A mega-show badge scan list is mostly noise for a neuro-oncology vendor; at SNO, nearly every badge on the floor belongs to someone who treats brain tumors, researches them, or runs the program that buys for them. At mid-tier booth pricing against that audience, SNO is one of the most cost-efficient specialty meetings in medicine, which is why it scores a 7.0 in our conference database despite its modest size.

Pre-Conference Strategy: Target Tumor Boards, Not Job Titles

Neuro-oncology purchasing decisions are made by teams. A neuronavigation platform, an intraoperative imaging system, or a new diagnostic assay gets adopted when the tumor board, the neurosurgery division, and the cancer center administration align, not when one enthusiastic attendee scans a badge. Build your pre-show targeting around institutions, then map the people.

Build an institution-level target list by early October. Start with the NCI-designated cancer centers and the 100-150 highest-volume brain tumor programs in your geography, then identify the SNO-attending names inside each: the neurosurgical oncologist, the neuro-oncologist who chairs the tumor board, the radiation oncologist with CNS focus, and the administrator who owns the capital request. Aim for 60-120 named targets tied to 30-50 institutions, with the specific clinical or trial decision each program is facing in the next 12 months.

Run a five-touch sequence starting six to eight weeks out. The cadence that reliably books meetings with academic physicians: a personalized email referencing their recent publication or open trial, a LinkedIn connection from your clinical or medical affairs lead, a value-led follow-up with a peer-reviewed reference, a specific Philadelphia meeting-slot offer, and a final confirmation the week before. Our pre-conference email campaigns guide covers the templates and timing in detail.

Book around the poster halls. SNO is a science-first meeting; attendees plan their days around abstracts, platform sessions, and posters, not the exhibit hall. Review the abstract schedule when it publishes, note when your target institutions are presenting, and schedule booth meetings and dinners in the gaps. Vendors who treat the scientific program as the meeting's spine, and the exhibit floor as its hallway, consistently out-book vendors who wait at the booth.

Booth Design for a Science-First, Pharma-Heavy Floor

The SNO exhibit floor is dominated by pharmaceutical and biotech companies with large footprints and deep sponsorship budgets. A device or diagnostics vendor cannot out-spend that presence, and should not try. The winning position is out-evidencing it at the scale of a focused booth.

Build around three elements. Evidence first: peer-reviewed citations, trial data with n-values, and registry outcomes displayed where they can be read from the aisle. This audience reads your data closely and will notice what is missing. Demonstration second: if you sell navigation, intraoperative imaging, or pathology equipment, the convention center venue supports real hardware; a working demo station outperforms any rendering. Specificity third: your graphics should answer, within 30 seconds, what the product does in a brain tumor case, what the evidence says, and which programs already use it. Generic oncology messaging signals that you do not know this specialty. Our medical conference booth design playbook covers layout and signage hierarchy for exactly this kind of floor.

One more Philadelphia-specific note: because pharma dominates attention with symposia and lounges, small vendors get outsized returns from precision, a focused booth, pre-booked meetings, and one well-chosen sponsorship, rather than trying to match share of voice.

On-Site Tactics: KOLs, Fellows, and the Tumor Board Conversation

SNO is a key opinion leader meeting. The neuro-oncology world is small, the same faculty anchor the major trials, and adoption flows downhill from a handful of high-volume academic programs. Your on-site plan should reflect that structure.

Prioritize structured KOL conversations over lead volume. Twenty scheduled 20-minute conversations with tumor board chairs and division chiefs will produce more pipeline than 300 badge scans. Staff the booth with clinical specialists and medical affairs, not generalist reps; this audience disengages quickly from anyone who cannot discuss the literature.

Invest in fellows and early-career researchers. Neuro-oncology fellows at SNO become the attendings making first-time technology decisions within three to five years, and the specialty is small enough that those relationships compound visibly. A fellows-focused touchpoint, an educational resource, hands-on demo access, or a small sponsored session, is one of the cheapest long-term investments on this floor.

Tier your follow-up on site. Target-list institutions get same-day scheduling for a post-show call or site visit. High-fit walk-ups get a structured nurture with clinical content. Everyone else, including the substantial international cohort, goes into a long-cycle track keyed to their region's procurement realities.

Post-SNO Follow-Up: Converting an Academic Buying Cycle

Almost every meaningful SNO lead is an academic medical center lead, and academic buying runs on committees, trials, and budget calendars rather than quarterly quotas. Capital equipment, navigation, intraoperative imaging, radiation therapy systems, moves through value analysis and capital committees on 9-18 month timelines. Diagnostics and consumables move faster once a champion commits, but still route through lab directors and pathology. Clinical trial services convert on the cadence of trial startup, not sales pressure.

The discipline that pays: within two weeks of Philadelphia, every target-institution conversation should have a scheduled next step, a site visit, a tumor board presentation, an evaluation protocol, or a budget-cycle check-in placed on the calendar for when the program's fiscal year opens. Our post-conference follow-up playbook covers the segmentation and CRM cadence, and our conference marketing ROI framework shows how to model a show like SNO against an 18-month academic pipeline so leadership judges the investment on the right clock.

Should You Exhibit at SNO in 2026?

Yes, if brain and CNS tumors are your market. Neurosurgical navigation, intraoperative imaging, radiation therapy equipment, brain tumor biomarkers and diagnostics, neuropathology systems, CNS drug delivery platforms, and clinical trial services all find their most concentrated possible audience here, at a cost per qualified buyer that mega-shows cannot match. Pair it with the broader playbooks in our oncology device marketing and neurology device marketing guides and SNO becomes the anchor event of a neuro-oncology go-to-market calendar.

No, if your product lacks a direct brain or CNS tumor application. The audience is deliberately narrow, the floor is science and pharma driven, and general surgical or imaging products will not find qualified buyers. Vendors weighing a broader imaging play should read our SNO vs RSNA comparison: SNO for depth in neuro-oncology, RSNA for reach across radiology. And if you only take one thing from this guide, take this: at a 3,000-person KOL meeting, preparation is the whole game. The vendors who leave Philadelphia with pipeline booked their meetings in September and October.